Biotech Licensing Often More Cost-Effective Than In-House R&D For Pharma

Large pharmaceutical manufacturers are entering into more early stage licensing deals with biotechs because such deals are often more cost-effective than conducting in-house research, Bayer VP-Business Development Chris Seaton said